Forte Biosciences Inc./$FBRX
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
- Ticker
- $FBRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 22
- Headquarters
- Dallas, United States
- Website
- www.fortebiorx.com
FBRX Metrics
BasicAdvanced
$1.9bn
-
-$4.65
2.87
-
Price and volume
Market cap
$1.9bn
Beta
2.87
52-week high
$77.20
52-week low
$9.91
Average daily volume
1.9m
Financial strength
Current ratio
2.753
Quick ratio
2.49
Profitability
EBITDA (TTM)
-76.902
Effective tax rate (TTM)
-1.89%
Management effectiveness
Return on assets (TTM)
-83.90%
Return on equity (TTM)
-188.40%
Valuation
Price to book
32.59
Price to tangible book (TTM)
32.59
Price to free cash flow (TTM)
-21.108
Free cash flow yield (TTM)
-4.74%
Free cash flow per share (TTM)
-3.637
Growth
Earnings per share change (TTM)
-43.62%
3-year earnings per share growth (CAGR)
-42.02%
FBRX News
AllArticlesVideos
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Business Wire2 days ago
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire5 days ago
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.